Data updated: Jun 28, 2026
CML Clinical Trial Landscape
CML is being studied across 398 clinical trials registered since 2008, with 121 programs currently active. The competitive pipeline includes 8 active Phase 3 trials, 79 active Phase 2 trials, and 32 active Phase 1 trials.
Top industry sponsors include Novartis, Shenzhen TargetRx Co., Ltd., Jiangsu Hansoh Pharmaceutical Co., Ltd..
Trial activity
121 active / 398 total since 2008
Active by phase 8 Ph3 / 44 79 Ph2 / 216 32 Ph1 / 115 2 Ph4 / 23
Sponsor activity
Who is running trials now — green active, blue completed, red failed/terminated.
Sorted by active Active Done Failed
Novartis 6 35 5
Shenzhen TargetRx Co., Ltd. 4 2 0
Jiangsu Hansoh Pharmaceutical Co., Ltd. 3 1 0
Ascentage Pharma Group Inc. 2 3 0
Enliven Therapeutics 2 0 0
Il-Yang Pharm. Co., Ltd. 2 0 0
Incyte Biosciences International Sàrl 1 0 0
Crossbow Therapeutics, Inc. 1 0 0
Ossium Health, Inc. 1 0 0
MacroGenics 1 0 0
Terns, Inc. 1 0 0
Orca Biosystems, Inc. 1 0 0
Otsuka Beijing Research Institute 1 0 0
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. 1 0 0
Kartos Therapeutics, Inc. 1 0 0
All 15 active CML sponsors
Unlock the remaining 7 sponsors with active / completed / failed counts — sortable and exportable.
Unlock with ProHow the field has grown
New-trial starts peaked in 2018 (25 registered); 2025 saw 14. The right-hand chart shows median Phase 3 enrollment by start year — the number in parentheses is that year's Phase 3 trial count (17 in total), so single-trial years (and years with no Phase 3 starts) are obvious. Both are by trial start date; the current year is partial.
New trials started by year
2016 21
2017 20
2018 25
2019 22
2020 19
2021 18
2022 17
2023 11
2024 20
2025 14
2026 11
TheraRadar.com
Median Phase 3 enrollment by start year
2016 (1) 125
2017 (3) 214
2018 (3) 173
2019 (2) 256
2020 (0) 0
2021 (3) 199
2022 (1) 568
2023 (2) 89
2024 (1) 285
2025 (0) 0
2026 (1) 180
TheraRadar.com
Full trial pipeline
Every active and completed trial across Phase 1–4, with enrollment analytics. Sortable, filterable, exportable with Pro.
NCT05753384 ACTIVE NOT RECRUITING
Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System
Poitiers University Hospital n=170
NCT04971226 ACTIVE NOT RECRUITING
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Novartis Pharmaceuticals n=405
NCT07489755 NOT YET RECRUITING
TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients
Shenzhen TargetRx Co., Ltd. n=180
NCT03480360 ACTIVE NOT RECRUITING
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
Dartmouth-Hitchcock Medical Center n=21
NCT05456191 ACTIVE NOT RECRUITING
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
Novartis Pharmaceuticals n=568
NCT06423911 RECRUITING
Study of Olverembatinib (HQP1351) in Patients With CP-CML
Ascentage Pharma Group Inc. n=285
NCT03722420 ACTIVE NOT RECRUITING
Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)
Il-Yang Pharm. Co., Ltd. n=238
NCT03459534 RECRUITING
A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs
Il-Yang Pharm. Co., Ltd. n=173
NCT01231412 COMPLETED
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Fred Hutchinson Cancer Center n=174
NCT01366612 TERMINATED
Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation
Hackensack Meridian Health n=53
NCT04948333 COMPLETED
Asciminib Treatment Optimization in ≥ 3rd Line CML-CP
Novartis Pharmaceuticals n=199
NCT02730299 COMPLETED
Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS
Gamida Cell ltd n=125
NCT04666259 COMPLETED
Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation
Novartis Pharmaceuticals n=56
NCT02201459 COMPLETED
Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients
Hospices Civils de Lyon n=200
NCT05413915 TERMINATED
Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML
Sarit Assouline n=8
NCT03106779 COMPLETED
Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs
Novartis Pharmaceuticals n=233
NCT03746054 TERMINATED
Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the Cardiovascular Morbi-mortality
University Hospital, Angers n=80
NCT03959241 COMPLETED
TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)
Medical College of Wisconsin n=431
NCT01428635 COMPLETED
Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy
M.D. Anderson Cancer Center n=21
NCT01951885 COMPLETED
Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention
Case Comprehensive Cancer Center n=101
NCT01657604 COMPLETED
TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study
University of Jena n=717
NCT03117816 COMPLETED
ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission
Philipps University Marburg n=214
NCT02566395 COMPLETED
Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies
Northwell Health n=10
NCT02627677 TERMINATED
A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia
Ariad Pharmaceuticals n=44
NCT01743989 COMPLETED
A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.
Novartis Pharmaceuticals n=620
NCT02707393 COMPLETED
Allogeneic Stem Cell Transplantation for Children With CML
St. Anna Kinderkrebsforschung n=13
NCT02115386 TERMINATED
Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to Nilotinib
Novartis Pharmaceuticals n=7
NCT02174445 TERMINATED
An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years
Prof. Dr. Nikolas von Bubnoff n=14
NCT01305200 COMPLETED
Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant
Children's Oncology Group n=226
NCT03079505 TERMINATED
Dasatinib Versus Nilotinib for Treatment Naïve Chronic Myeloid Leukemia
Hamad Medical Corporation n=10
NCT00574873 COMPLETED
Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML
Pfizer n=502
NCT01535391 COMPLETED
Nilotinib in PH+, BCR-, ABL+ CML Patients
Gruppo Italiano Malattie EMatologiche dell'Adulto n=109
NCT01755325 SUSPENDED
Phase III Study of Compound Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib in Adult CML-CP Patients With Ph+
Junmin Li n=680
NCT02204644 COMPLETED
The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML
Jiangsu Hansoh Pharmaceutical Co., Ltd. n=400
NCT01749111 TERMINATED
Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis
Hospital Israelita Albert Einstein n=3
NCT01126892 COMPLETED
A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase
Novartis Pharmaceuticals n=6
NCT00760877 COMPLETED
Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)
Novartis Pharmaceuticals n=207
NCT01275196 COMPLETED
Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients
Novartis Pharmaceuticals n=267
NCT01254188 COMPLETED
Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients
Novartis Pharmaceuticals n=421
NCT00802841 COMPLETED
Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib
Novartis Pharmaceuticals n=191
NCT01650805 TERMINATED
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Ariad Pharmaceuticals n=307
NCT02103322 COMPLETED
Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions
Amneal Pharmaceuticals, LLC n=48
NCT00799461 COMPLETED
Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium n=1,337
NCT02506933 ACTIVE NOT RECRUITING
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant
City of Hope Medical Center
NCT06236724 RECRUITING
Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
M.D. Anderson Cancer Center
NCT07468916 NOT YET RECRUITING
Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia
Jonsson Comprehensive Cancer Center
NCT05092451 RECRUITING
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
NCT07269470 NOT YET RECRUITING
Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
M.D. Anderson Cancer Center
NCT03817398 ACTIVE NOT RECRUITING
Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia
Children's Oncology Group
NCT04626024 ACTIVE NOT RECRUITING
Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population
Baylor College of Medicine
NCT07354074 RECRUITING
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Novartis Pharmaceuticals
NCT06514534 RECRUITING
Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.
Novartis Pharmaceuticals
NCT07538401 NOT YET RECRUITING
ASCiminib, With or Without Dasatinib Combination, as a 2nd-Line Therapy to ADVANCE the Treatment for Chronic Myelogenous Leukemia in Chronic Phase (ASC2ADVANCE)
University Health Network, Toronto
NCT03934372 RECRUITING
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Incyte Biosciences International Sàrl
NCT06817720 RECRUITING
Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
M.D. Anderson Cancer Center
NCT01424982 ACTIVE NOT RECRUITING
Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT03192397 ACTIVE NOT RECRUITING
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Roswell Park Cancer Institute
NCT03289910 ACTIVE NOT RECRUITING
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
National Cancer Institute (NCI)
NCT03849651 ACTIVE NOT RECRUITING
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
St. Jude Children's Research Hospital
NCT03516279 ACTIVE NOT RECRUITING
Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
ECOG-ACRIN Cancer Research Group
NCT03610971 ACTIVE NOT RECRUITING
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors
H. Lee Moffitt Cancer Center and Research Institute
NCT06368414 RECRUITING
A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia
Korean Society of Hematology
NCT07493408 NOT YET RECRUITING
Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML
The University of Hong Kong
NCT05143840 RECRUITING
Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase
University of Alabama at Birmingham
NCT04904588 ACTIVE NOT RECRUITING
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
Center for International Blood and Marrow Transplant Research
NCT06859424 RECRUITING
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Center for International Blood and Marrow Transplant Research
NCT06523556 RECRUITING
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
Uma Borate
NCT03862157 ACTIVE NOT RECRUITING
Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT06059391 RECRUITING
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
City of Hope Medical Center
NCT01746836 RECRUITING
Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
M.D. Anderson Cancer Center
NCT02689440 ACTIVE NOT RECRUITING
Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
NCT05768711 ACTIVE NOT RECRUITING
Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)
Groupe Francophone des Myelodysplasies
NCT04195633 RECRUITING
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Fred Hutchinson Cancer Center
NCT03263572 RECRUITING
Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT05589896 RECRUITING
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Ossium Health, Inc.
NCT05007873 RECRUITING
ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase
M.D. Anderson Cancer Center
NCT03147612 ACTIVE NOT RECRUITING
Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT04761770 ACTIVE NOT RECRUITING
Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders
Memorial Sloan Kettering Cancer Center
NCT02861417 ACTIVE NOT RECRUITING
Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
M.D. Anderson Cancer Center
NCT06001385 ACTIVE NOT RECRUITING
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
Center for International Blood and Marrow Transplant Research
NCT03842696 ACTIVE NOT RECRUITING
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
University of Michigan Rogel Cancer Center
NCT06013423 RECRUITING
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Fred Hutchinson Cancer Center
NCT06163430 RECRUITING
A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)
Terns, Inc.
NCT03674411 ACTIVE NOT RECRUITING
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
Masonic Cancer Center, University of Minnesota
NCT03654768 ACTIVE NOT RECRUITING
Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia
SWOG Cancer Research Network
NCT03622788 ACTIVE NOT RECRUITING
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
M.D. Anderson Cancer Center
NCT07259161 NOT YET RECRUITING
Modified Conditioning Regimen for CML-BP
Institute of Hematology & Blood Diseases Hospital, China
NCT03589729 RECRUITING
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
M.D. Anderson Cancer Center
NCT07238712 RECRUITING
Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor
St. Petersburg State Pavlov Medical University
NCT04070443 ACTIVE NOT RECRUITING
Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase
Centre Leon Berard
NCT04060277 ACTIVE NOT RECRUITING
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
City of Hope Medical Center
NCT02115295 RECRUITING
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
M.D. Anderson Cancer Center
NCT05384587 ACTIVE NOT RECRUITING
Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia
Novartis Pharmaceuticals
NCT02917720 ACTIVE NOT RECRUITING
2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients
European LeukemiaNet
NCT04258943 ACTIVE NOT RECRUITING
Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia
Children's Oncology Group
NCT05884333 RECRUITING
Cord Blood Transplant in Adults With Blood Cancers
Memorial Sloan Kettering Cancer Center
NCT07022743 ACTIVE NOT RECRUITING
Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination Therapy
Obafemi Awolowo University
NCT03399773 ACTIVE NOT RECRUITING
Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes
Fred Hutchinson Cancer Center
NCT02790515 ACTIVE NOT RECRUITING
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
St. Jude Children's Research Hospital
NCT04838041 RECRUITING
Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
Medical College of Wisconsin
NCT06409936 RECRUITING
PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
Gruppo Italiano Malattie EMatologiche dell'Adulto
NCT05805605 RECRUITING
Allo HSCT Using RIC and PTCy for Hematological Diseases
Masonic Cancer Center, University of Minnesota
NCT06802315 RECRUITING
Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)
University of Illinois at Chicago
NCT03314974 RECRUITING
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Masonic Cancer Center, University of Minnesota
NCT05800210 RECRUITING
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
University of Florida
NCT06757855 RECRUITING
Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML
Institute of Hematology & Blood Diseases Hospital, China
NCT06355583 RECRUITING
Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial
Imperial College London
NCT04233346 ACTIVE NOT RECRUITING
The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation
Otsuka Beijing Research Institute
NCT05701215 ACTIVE NOT RECRUITING
Venetoclax After TKI to Target Persisting Stem Cells in CML
Thomas Ernst, PD Dr. med.
NCT03906292 ACTIVE NOT RECRUITING
Frontline Asciminib Combination in Chronic Phase CML
University of Jena
NCT06453902 RECRUITING
TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients
Shenzhen TargetRx Co., Ltd.
NCT04160546 ACTIVE NOT RECRUITING
Study to Evaluate the Reinduction and Second Stop of TKI with Ponatinib in CML in Molecular Response (ResToP)
Fundacion CRIS de Investigación para Vencer el Cáncer
NCT04147533 ACTIVE NOT RECRUITING
Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid Leukemia
Masaryk University
NCT06532084 RECRUITING
Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen
St. Petersburg State Pavlov Medical University
NCT06508099 RECRUITING
Vitamin A and D Supplementation in Allogeneic HCT
St. Petersburg State Pavlov Medical University
NCT02061800 ACTIVE NOT RECRUITING
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
Diane George
NCT03852407 RECRUITING
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning
University of Liege
NCT02629692 TERMINATED
Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ���3 Prior CML Therapies
Sun Pharma Advanced Research Company Limited
NCT03578367 COMPLETED
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Novartis Pharmaceuticals
NCT05322850 SUSPENDED
Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)
University of Florida
NCT03874858 COMPLETED
A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia
Novartis Pharmaceuticals
NCT04216563 TERMINATED
ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor
M.D. Anderson Cancer Center
NCT05115630 COMPLETED
Off-the-shelf NK Cells + SCT for Myeloid Malignancies
M.D. Anderson Cancer Center
NCT04191187 COMPLETED
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
H. Lee Moffitt Cancer Center and Research Institute
NCT04188405 COMPLETED
Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
NCT01760655 COMPLETED
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT01784068 COMPLETED
Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients
Novartis Pharmaceuticals
NCT01698905 COMPLETED
Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)
Novartis Pharmaceuticals
NCT01660607 COMPLETED
Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell
Stanford University
NCT03333486 TERMINATED
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Roswell Park Cancer Institute
NCT02722668 COMPLETED
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Masonic Cancer Center, University of Minnesota
NCT00674479 COMPLETED
INCB018424 in Patients With Advanced Hematologic Malignancies
M.D. Anderson Cancer Center
NCT03831776 COMPLETED
Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis
St. Olavs Hospital
NCT02220985 COMPLETED
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
Fred Hutchinson Cancer Center
NCT03246906 TERMINATED
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Fred Hutchinson Cancer Center
NCT01350245 COMPLETED
Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT03576547 TERMINATED
Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
NCT03615105 TERMINATED
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
Memorial Sloan Kettering Cancer Center
NCT04126681 COMPLETED
A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase
Ascentage Pharma Group Inc.
NCT02396134 COMPLETED
Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
NCT02398825 TERMINATED
Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib
Gruppo Italiano Malattie EMatologiche dell'Adulto
NCT04083170 TERMINATED
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
Fred Hutchinson Cancer Center
NCT00965224 COMPLETED
Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma
Zwi Berneman
NCT03941769 COMPLETED
2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II
M.D. Anderson Cancer Center
NCT04151706 COMPLETED
CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML
Robert Lowsky
NCT04943757 COMPLETED
Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies
St. Petersburg State Pavlov Medical University
NCT05433532 COMPLETED
Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients
The First Affiliated Hospital of Soochow University
NCT04793399 TERMINATED
Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients
Fundacion Espanola para la Curacion de la Leucemia Mieloide Cronica
NCT01858740 COMPLETED
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children
Fred Hutchinson Cancer Center
NCT01904136 COMPLETED
Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
NCT03128359 COMPLETED
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
City of Hope Medical Center
NCT05201183 WITHDRAWN
A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies
Naoyuki G. Saito, M.D., Ph.D.
NCT03455517 COMPLETED
Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto
NCT02639559 COMPLETED
Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies
Washington University School of Medicine
NCT01823198 COMPLETED
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies
M.D. Anderson Cancer Center
NCT03096782 COMPLETED
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
M.D. Anderson Cancer Center
NCT03625388 COMPLETED
Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Hikma Pharmaceuticals LLC
NCT02661035 COMPLETED
Allo HSCT Using RIC for Hematological Diseases
Masonic Cancer Center, University of Minnesota
NCT01696461 COMPLETED
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
Center for International Blood and Marrow Transplant Research
NCT01044745 TERMINATED
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
University of Nebraska
NCT03267186 COMPLETED
Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant
Andrew Rezvani
NCT02311998 COMPLETED
Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML
M.D. Anderson Cancer Center
NCT01572662 COMPLETED
Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning
M.D. Anderson Cancer Center
NCT01593254 COMPLETED
Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib
Bristol-Myers Squibb
NCT02581007 COMPLETED
Reduced Intensity Conditioning Transplant Using Haploidentical Donors
Northside Hospital, Inc.
NCT00796068 COMPLETED
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant
Fred Hutchinson Cancer Center
NCT02743351 COMPLETED
Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies
Fate Therapeutics
NCT02810990 COMPLETED
Bosutinib in Elderly Chronic Myeloid Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto
NCT02593123 COMPLETED
Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis
Virginia Commonwealth University
NCT00739141 COMPLETED
Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.
Memorial Sloan Kettering Cancer Center
NCT02556931 COMPLETED
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01850004 COMPLETED
Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response
Bristol-Myers Squibb
NCT04282174 WITHDRAWN
CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies
Baptist Health South Florida
NCT04006847 TERMINATED
Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Milton S. Hershey Medical Center
NCT01667133 COMPLETED
A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)
Ariad Pharmaceuticals
NCT00968864 TERMINATED
T-cell Depleted Alternative Donor Transplantation
Wake Forest University Health Sciences
NCT02353728 COMPLETED
Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy
Weill Medical College of Cornell University
NCT02795520 TERMINATED
Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia
OncoTherapy Science, Inc.
NCT02078960 TERMINATED
A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)
Teva Branded Pharmaceutical Products R&D, Inc.
NCT00644878 TERMINATED
Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib
Novartis Pharmaceuticals
NCT01690520 COMPLETED
Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes
Nohla Therapeutics, Inc.
NCT03602898 WITHDRAWN
Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation
Fred Hutchinson Cancer Center
NCT00860574 COMPLETED
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia
Fred Hutchinson Cancer Center
NCT04883125 COMPLETED
Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment
Mansoura University
NCT01844765 COMPLETED
Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.
Novartis Pharmaceuticals
NCT01338987 COMPLETED
Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation
National Cancer Institute (NCI)
NCT01216085 COMPLETED
An Exploratory Study of High-dose Glivec in Patients With CML-CP Using Molecular Endpoints
Novartis Pharmaceuticals
NCT01207440 COMPLETED
Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)
Ariad Pharmaceuticals
NCT01474681 COMPLETED
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
Novartis Pharmaceuticals
NCT03739606 WITHDRAWN
Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer
City of Hope Medical Center
NCT02092324 COMPLETED
Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia
OHSU Knight Cancer Institute
NCT01914484 COMPLETED
Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia
University Health Network, Toronto
NCT02991898 TERMINATED
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies
Masonic Cancer Center, University of Minnesota
NCT01274351 COMPLETED
Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Novartis Pharmaceuticals
NCT01885897 COMPLETED
IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT
Masonic Cancer Center, University of Minnesota
NCT02923986 WITHDRAWN
Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS
Bio-Path Holdings, Inc.
NCT02906696 TERMINATED
Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI Failure
M.D. Anderson Cancer Center
NCT01744665 COMPLETED
A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation
Novartis Pharmaceuticals
NCT01872442 COMPLETED
Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic Phase
Poitiers University Hospital
NCT00789776 COMPLETED
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
NCT01527045 COMPLETED
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies
Fred Hutchinson Cancer Center
NCT00723099 COMPLETED
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
NCT01251575 COMPLETED
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT03195010 TERMINATED
Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia
Fred Hutchinson Cancer Center
NCT01529827 COMPLETED
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Roswell Park Cancer Institute
NCT01839916 COMPLETED
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
University of Chicago
NCT01159067 TERMINATED
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
City of Hope Medical Center
NCT01294618 COMPLETED
Nilotinib + Pegylated Interferon Alpha 2a for Untreated Chronic Phase Chronic Myelogenous Leukemia
Hospices Civils de Lyon
NCT01175785 COMPLETED
Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies
Nohla Therapeutics, Inc.
NCT02208037 COMPLETED
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
National Heart, Lung, and Blood Institute (NHLBI)
NCT02730195 TERMINATED
Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia
Emory University
NCT03438344 WITHDRAWN
Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
NCT00709592 COMPLETED
Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT
Virginia Commonwealth University
NCT02709083 TERMINATED
Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia
Emory University
NCT01789255 COMPLETED
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies
National Cancer Institute (NCI)
NCT01517035 COMPLETED
Improving Blood Stem Cell Collection and Transplant Procedures
National Heart, Lung, and Blood Institute (NHLBI)
NCT01050764 TERMINATED
Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells
Everett Meyer
NCT02877082 TERMINATED
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
Emory University
NCT01564277 TERMINATED
Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies
Roswell Park Cancer Institute
NCT02765997 WITHDRAWN
StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies
Masonic Cancer Center, University of Minnesota
NCT01163201 WITHDRAWN
T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies
Masonic Cancer Center, University of Minnesota
NCT00852566 COMPLETED
Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia
Norwegian University of Science and Technology
NCT01606579 COMPLETED
Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies
Prism Pharma Co., Ltd.
NCT00702403 COMPLETED
Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML
Fred Hutchinson Cancer Center
NCT01167166 COMPLETED
Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)
Traws Pharma, Inc.
NCT02259348 TERMINATED
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
St. Jude Children's Research Hospital
NCT00795769 COMPLETED
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT01427881 COMPLETED
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
Fred Hutchinson Cancer Center
NCT02200380 TERMINATED
A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs
Celldex Therapeutics
NCT00815321 COMPLETED
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy
Singapore General Hospital
NCT01916785 COMPLETED
OPTIM DASATINIB (Optimized Tyrosine Kinase Inhibitors Monotherapy)
Versailles Hospital
NCT02115672 WITHDRAWN
Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia
Sheba Medical Center
NCT01652014 WITHDRAWN
Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies
University of Medicine and Dentistry of New Jersey
NCT01297543 COMPLETED
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia
Cellerant Therapeutics
NCT01036009 COMPLETED
A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies
University of California, San Francisco
NCT00750659 COMPLETED
Nilotinib Pre and Post Allogeneic Stem Cell Transplantation
Sheba Medical Center
NCT01019317 COMPLETED
Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
NCT00975975 COMPLETED
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer
Indiana University
NCT01413568 COMPLETED
Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies
Polyphor Ltd.
NCT01390402 COMPLETED
Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG
M.D. Anderson Cancer Center
NCT01670084 WITHDRAWN
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia
Mayo Clinic
NCT00866736 COMPLETED
A Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia
Kanto CML Study Group
NCT01342679 COMPLETED
A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib
Kanto CML Study Group
NCT00954941 COMPLETED
Ondansetron Versus Aprepitant Plus Ondansetron for Emesis
M.D. Anderson Cancer Center
NCT01188889 WITHDRAWN
RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.
University of Michigan Rogel Cancer Center
NCT01819558 COMPLETED
Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy
Institut Paoli-Calmettes
NCT00858806 COMPLETED
Intermittent Imatinib Treatment in Chronic Myeloid Leukemia and Philadelphia Chromosome (Ph+CML) Patients Who Achieved a Complete Cytogenetic Response (CCgR) on Standard Imatinib Therapy
Università degli Studi di Brescia
NCT01500161 TERMINATED
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
Texas Oncology Cancer Center
NCT00570999 WITHDRAWN
Palifermin After Haploidentical PBSCT
European Society for Blood and Marrow Transplantation
NCT00719836 COMPLETED
A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies
S*BIO
NCT00895297 TERMINATED
Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia
European Society for Blood and Marrow Transplantation
NCT01011998 WITHDRAWN
A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML)
New Mexico Cancer Research Alliance
NCT05088356 ACTIVE NOT RECRUITING
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
Stanford University
NCT06401603 RECRUITING
A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT07302776 NOT YET RECRUITING
TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
Stanford University
NCT07166419 RECRUITING
Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia
Ohio State University Comprehensive Cancer Center
NCT06047886 RECRUITING
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
University of Alabama at Birmingham
NCT07254793 NOT YET RECRUITING
Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT
University of Arizona
NCT05304377 RECRUITING
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
Enliven Therapeutics
NCT07020533 RECRUITING
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
City of Hope Medical Center
NCT03533816 RECRUITING
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
University of Kansas Medical Center
NCT06994676 RECRUITING
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
Crossbow Therapeutics, Inc.
NCT03630991 RECRUITING
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
M.D. Anderson Cancer Center
NCT05549661 RECRUITING
Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms
Mayo Clinic
NCT05362773 RECRUITING
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
MacroGenics
NCT02530034 ACTIVE NOT RECRUITING
Hu8F4 in Treating Patients With Advanced Hematologic Malignancies
M.D. Anderson Cancer Center
NCT03326310 RECRUITING
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
University of Chicago
NCT03560752 ACTIVE NOT RECRUITING
CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant
City of Hope Medical Center
NCT02091245 ACTIVE NOT RECRUITING
Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML
Dana-Farber Cancer Institute
NCT03326921 RECRUITING
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT04260022 RECRUITING
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Ascentage Pharma Group Inc.
NCT03595917 RECRUITING
ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
Marlise Luskin, MD
NCT05823571 ACTIVE NOT RECRUITING
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01494103 ACTIVE NOT RECRUITING
Administration of Donor T Cells With the Caspase-9 Suicide Gene
Baylor College of Medicine
NCT00710892 ACTIVE NOT RECRUITING
CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene
Baylor College of Medicine
NCT05857969 RECRUITING
Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Florida International University
NCT06787144 RECRUITING
ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants
Enliven Therapeutics
NCT04013685 ACTIVE NOT RECRUITING
Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Orca Biosystems, Inc.
NCT05434312 ACTIVE NOT RECRUITING
TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients
Shenzhen TargetRx Co., Ltd.
NCT06088888 RECRUITING
TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia
Shenzhen TargetRx Co., Ltd.
NCT06672263 NOT YET RECRUITING
A Clinical Trial to Evaluate the Safety and Tolerability of TQB3911 Tablets in Patients With BCR::ABL Fusion Gene Positive Leukemia
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
NCT06530810 NOT YET RECRUITING
Study of HS-10382 Combination in Patients With Chronic Myeloid Leukemia (CML)
Jiangsu Hansoh Pharmaceutical Co., Ltd.
NCT05367700 RECRUITING
A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
NCT07651878 RECRUITING
Phase I Trial of Vididencel in CML-CP Patients With MRD Under TKI Treatment
Mendus
NCT00720785 COMPLETED
Natural Killer Cells and Bortezomib to Treat Cancer
National Heart, Lung, and Blood Institute (NHLBI)
NCT02381548 TERMINATED
Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT04681105 COMPLETED
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
City of Hope Medical Center
NCT05400122 SUSPENDED
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
David Wald
NCT02996773 COMPLETED
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
University of Arizona
NCT05623774 COMPLETED
A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg
Inhibikase Therapeutics
NCT01290302 COMPLETED
Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza
American Regent, Inc.
NCT01751425 TERMINATED
Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors
M.D. Anderson Cancer Center
NCT00588991 COMPLETED
Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders
National Cancer Institute (NCI)
NCT04526795 TERMINATED
Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia
M.D. Anderson Cancer Center
NCT03884829 TERMINATED
A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS
Cyclacel Pharmaceuticals, Inc.
NCT01588015 COMPLETED
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
NCT02081378 COMPLETED
A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL
Novartis Pharmaceuticals
NCT03878524 TERMINATED
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
NCT01523223 COMPLETED
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies
Robert Lowsky
NCT02890758 COMPLETED
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803
Brenda Cooper, MD
NCT01756118 COMPLETED
A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia
Goethe University
NCT02960646 COMPLETED
Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
M.D. Anderson Cancer Center
NCT03696537 TERMINATED
IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT
Naoyuki G. Saito, M.D., Ph.D.
NCT02730312 COMPLETED
PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies
Xencor, Inc.
NCT03519984 TERMINATED
EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia
University of Southern California
NCT04464889 WITHDRAWN
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
Medigene AG
NCT03018223 COMPLETED
Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT
H. Lee Moffitt Cancer Center and Research Institute
NCT04126707 COMPLETED
The Absorption, Metabolism and Excretion of [14C] HQP1351 in Humans
Ascentage Pharma Group Inc.
NCT01822509 COMPLETED
Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant
National Cancer Institute (NCI)
NCT02129582 COMPLETED
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies
Case Comprehensive Cancer Center
NCT01702064 COMPLETED
Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients
H. Lee Moffitt Cancer Center and Research Institute
NCT01077544 COMPLETED
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
Novartis Pharmaceuticals
NCT01456676 COMPLETED
Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy
Novartis Pharmaceuticals
NCT01223898 COMPLETED
To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib
Novartis Pharmaceuticals
NCT02782403 TERMINATED
Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia
M.D. Anderson Cancer Center
NCT00674427 TERMINATED
Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant
University of Pennsylvania
NCT03807063 WITHDRAWN
Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT01159028 COMPLETED
Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS
Bio-Path Holdings, Inc.
NCT02011945 COMPLETED
A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia
Bristol-Myers Squibb
NCT03882281 COMPLETED
Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia
Ascentage Pharma Group Inc.
NCT02231853 TERMINATED
Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections
National Heart, Lung, and Blood Institute (NHLBI)
NCT02253277 COMPLETED
Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients
Novartis Pharmaceuticals
NCT01849276 TERMINATED
Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML
Northwestern University
NCT01634217 COMPLETED
Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation
Masonic Cancer Center, University of Minnesota
NCT01933906 COMPLETED
Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response
Arbeitsgemeinschaft medikamentoese Tumortherapie
NCT03414450 WITHDRAWN
Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
NCT02728700 TERMINATED
Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT
Stanford University
NCT01397734 TERMINATED
Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)
Beth Israel Deaconess Medical Center
NCT01484015 COMPLETED
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia
Wake Forest University Health Sciences
NCT02226861 COMPLETED
Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation
National Heart, Lung, and Blood Institute (NHLBI)
NCT00660920 COMPLETED
Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies
Ariad Pharmaceuticals
NCT01207076 TERMINATED
AHN-12 Biodistribution in Advanced Leukemia
Masonic Cancer Center, University of Minnesota
NCT01110473 COMPLETED
ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies
AbbVie (prior sponsor, Abbott)
NCT02564536 WITHDRAWN
Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)
Washington University School of Medicine
NCT02047149 TERMINATED
Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous Leukemia
University of Massachusetts, Worcester
NCT00891592 COMPLETED
Umbilical Cord Blood Transplant for Hematological Malignancies
University of Pennsylvania
NCT01075425 COMPLETED
Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome
Virginia Commonwealth University
NCT00860535 TERMINATED
Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED)
Merck Sharp & Dohme LLC
NCT01658319 COMPLETED
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies
Case Comprehensive Cancer Center
NCT00990587 COMPLETED
Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy
University Health Network, Toronto
NCT01344876 COMPLETED
Phase I Study of OPB-51602 in Patients With Hematologic Malignancies
Otsuka Pharmaceutical Co., Ltd.
NCT01130688 TERMINATED
Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML.
University of Massachusetts, Worcester
NCT01795716 COMPLETED
Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT01149915 COMPLETED
Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias
Threshold Pharmaceuticals
NCT01220648 COMPLETED
Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP)
Novartis Pharmaceuticals
NCT01751919 COMPLETED
A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I)
Dong-A ST Co., Ltd.
NCT00964873 COMPLETED
A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia
Synta Pharmaceuticals Corp.
NCT00858572 COMPLETED
STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders
Synta Pharmaceuticals Corp.
NCT00827138 COMPLETED
Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation)
Deciphera Pharmaceuticals, LLC
NCT00933985 TERMINATED
Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia
National Cancer Institute (NCI)
NCT01231919 COMPLETED
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
National Cancer Institute (NCI)
NCT01426334 TERMINATED
Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate
National Cancer Institute (NCI)
NCT00890747 COMPLETED
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
National Cancer Institute (NCI)
NCT00866346 WITHDRAWN
PR1-Specific Cytotoxic T-Lymphocyte Infusion With Recurrent Chronic Myelogenous Leukemia (CML) After Allogeneic Hematopoietic Transplantation
M.D. Anderson Cancer Center
NCT01068301 COMPLETED
A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation
St. Jude Children's Research Hospital
NCT01159301 TERMINATED
Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT00807677 COMPLETED
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies
Millennium Pharmaceuticals, Inc.
NCT01270984 COMPLETED
Study to Evaluate the Pharmacokinetic Characteristics of Luckyvec 400mg Tablet, in Healthy Subjects
Chong Kun Dang Pharmaceutical
NCT00684008 COMPLETED
Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant
Cytheris, Inc.
NCT01066468 TERMINATED
Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.
Novartis Pharmaceuticals
NCT01452334 WITHDRAWN
Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy
Bristol-Myers Squibb
NCT05367765 NOT YET RECRUITING
A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Jiangsu Hansoh Pharmaceutical Co., Ltd.
NCT01742299 COMPLETED
Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator
Novartis Pharmaceuticals
NCT06427811 COMPLETED
Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation
Novartis Pharmaceuticals
NCT01735955 COMPLETED
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
Novartis Pharmaceuticals
NCT02546674 COMPLETED
Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.
Novartis Pharmaceuticals
NCT02228382 TERMINATED
Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors
Pfizer
NCT00980018 COMPLETED
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
Novartis Pharmaceuticals
NCT04925141 COMPLETED
A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT01131325 TERMINATED
Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations
Novartis Pharmaceuticals
NCT01243489 COMPLETED
Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
NCT01578213 COMPLETED
Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients
University of Milano Bicocca
NCT02204722 TERMINATED
A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients
Dong-A ST Co., Ltd.
NCT01605981 WITHDRAWN
Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.
Novartis Pharmaceuticals
NCT01206088 COMPLETED
Tasigna in Glivec-resistant or Intolerant Patients in CML
Novartis Pharmaceuticals
NCT01061177 COMPLETED
Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase
Novartis Pharmaceuticals
NCT00786812 COMPLETED
Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase
Novartis Pharmaceuticals
NCT01660906 COMPLETED
Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
Bristol-Myers Squibb
NCT01368523 COMPLETED
Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial
Novartis Pharmaceuticals
NCT01043874 COMPLETED
Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response
Novartis Pharmaceuticals
NCT01227577 COMPLETED
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
Novartis Pharmaceuticals
Full CML Pipeline
Every trial across Phase 1–4, plus enrollment analytics. Sortable, filterable, exportable.
Unlock with ProData: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only